This NDC is on FDA's drug shortage list (posted Jul 14, 2023)
Product Information
VYVANSE 60 MG CHEWABLE TABLET is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $12.3650 per EA under NDC 59417012001. Its NADAC has been published 211 times since Sep 21, 2022.
FDA first approved this application on Jan 28, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the LISDEXAMFETAMINE DIMESYLATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
60 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
59417012001
Classification
Brand
Dosage Form
TABLET, CHEWABLE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LISDEXAMFETAMINE DIMESYLATEApproval Type
New Drug (NDA)
FDA Application
NDA208510FDA Approved
1/28/2017
TE Code
AB
On Market Since
1/28/2017
Pharmacological Classes
Price Statistics
The NADAC for VYVANSE 60 MG CHEWABLE TABLET has been published 211 times since Sep 21, 2022, and over the history we have for it it has risen 9.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.3650 per EA |
|---|---|
| All-time high | $12.4079 (Nov 13, 2024) |
| All-time low | $11.3047 (Sep 21, 2022) |
| 52-week high | $12.3689 |
| 52-week low | $12.3531 |
| Median price | $12.3556 |
| Average price | $12.1607 |
| Largest weekly change | +5.0% (Jan 3, 2024) |
| Weeks tracked | 211 |
| Tracking since | Sep 21, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the LISDEXAMFETAMINE DIMESYLATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
LISDEXAMFETAMINE DIMESYLATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VYVANSE 60 MG CHEWABLE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VYVANSE 60 MG CHEWABLE TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $12.3650 per EA (NDC 59417012001), effective Sep 30, 2026.
How has the price of VYVANSE 60 MG CHEWABLE TABLET changed over time?
Over the history we have for it, the NADAC for VYVANSE 60 MG CHEWABLE TABLET has risen 9.4%. It has been tracked across 211 weekly CMS publications since Sep 21, 2022.
What are the highest and lowest recorded NADAC prices for VYVANSE 60 MG CHEWABLE TABLET?
Since Sep 21, 2022, the NADAC for VYVANSE 60 MG CHEWABLE TABLET has ranged from a low of $11.3047 (Sep 21, 2022) to a high of $12.4079 (Nov 13, 2024), with a median of $12.3556 per EA.
Are there cheaper alternatives to VYVANSE 60 MG CHEWABLE TABLET?
No other NADAC-published product currently shares the active ingredient and strength of VYVANSE 60 MG CHEWABLE TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VYVANSE 60 MG CHEWABLE TABLET?
VYVANSE 60 MG CHEWABLE TABLET (NDC 59417012001) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.
Is VYVANSE 60 MG CHEWABLE TABLET in shortage?
Yes — NDC 59417012001 is currently listed in FDA's drug shortage database (posted Jul 14, 2023).